Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mesa Laboratories (MLAB) Cash & Equivalents: 2010-2025

Historic Cash & Equivalents for Mesa Laboratories (MLAB) over the last 16 years, with Sep 2025 value amounting to $20.4 million.

  • Mesa Laboratories' Cash & Equivalents fell 16.09% to $20.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.4 million, marking a year-over-year decrease of 16.09%. This contributed to the annual value of $27.3 million for FY2025, which is 3.17% down from last year.
  • Mesa Laboratories' Cash & Equivalents amounted to $20.4 million in Q3 2025, which was down 4.03% from $21.3 million recorded in Q2 2025.
  • In the past 5 years, Mesa Laboratories' Cash & Equivalents registered a high of $278.3 million during Q3 2021, and its lowest value of $20.4 million during Q3 2025.
  • Moreover, its 3-year median value for Cash & Equivalents was $28.2 million (2024), whereas its average is $27.9 million.
  • In the last 5 years, Mesa Laboratories' Cash & Equivalents soared by 224.24% in 2021 and then slumped by 88.37% in 2022.
  • Mesa Laboratories' Cash & Equivalents (Quarterly) stood at $51.7 million in 2021, then tumbled by 49.52% to $26.1 million in 2022, then increased by 8.13% to $28.2 million in 2023, then fell by 3.20% to $27.3 million in 2024, then decreased by 16.09% to $20.4 million in 2025.
  • Its Cash & Equivalents was $20.4 million in Q3 2025, compared to $21.3 million in Q2 2025 and $27.3 million in Q1 2025.